Radiosensitization by the novel DNA intercalating agent vosaroxin

Radiation Oncology

Kevin Camphausen¹  Philip Tofilon¹  Tamalee Kramp¹  Whoon J Kil¹  Christian Graves¹  Ira K Gordon¹ 

[1] Radiation Oncology Branch, National Cancer Institute, 10 Center Drive, MSC 1002, Bldg 10 Rm. B3B100, Bethesda, MD 20892, USA

关键词: Quinolone;    Naphthyridine;    SNS-595;    Vosaroxin;   

Others  :  1160890
DOI  :  10.1186/1748-717X-7-26

 received in 2011-11-28, accepted in 2012-02-27,  发布年份 2012

【 摘 要 】

Purpose

Vosaroxin is a first in class naphthyridine analog structurally related to quinolone antibacterials, that intercalates DNA and inhibits topoisomerase II. Vosaroxin is not a P-glycoprotein receptor substrate and its activity is independent of p53, thus evading common drug resistance mechanisms. To evaluate vosaroxin as a clinically applicable radiation sensitizer, we investigated its effects on tumor cell radiosensitivity in vitro and in vivo.

Methods

Vosaroxin's effect on post-irradiation sensitivity of U251, DU145, and MiaPaca-2 cells was assessed by clonogenic assay. Subsequent mechanistic and in vivo studies were performed with U251 cells. Cell cycle distribution and G2 checkpoint integrity was analyzed by flow cytometry. DNA damage and repair was evaluated by a high throughput gamma-H2AX assay. Apoptosis was assessed by flow cytometry. Mitotic catastrophe was assessed by microscopic evidence of fragmented nuclei by immunofluorescence. In vivo radiosensitization was measured by subcutaneous tumor growth delay.

Results

50-100 nmol/L treatment with vosaroxin resulted in radiosensitization of all 3 cell lines tested with a dose enhancement factor of 1.20 to 1.51 measured at a surviving fraction of 0.1. The maximal dose enhancement was seen in U251 cells treated with 75 nmol/L vosaroxin (DEF 1.51). Vosaroxin exposure did not change cell cycle distribution prior to irradiation nor alter G2 checkpoint integrity after irradiation. No difference was seen in the apoptotic fraction regardless of drug or radiation treatment. The number of cells in mitotic catastrophe was significantly greater in irradiated cells treated with vosaroxin than cells receiving radiation only at 72 hr (p = 0.009). Vosaroxin alone did not significantly increase mitotic catastrophe over control (p = 0.53). Cells treated with vosaroxin and radiation maintained significantly higher gamma-H2AX levels than cells treated with vehicle control (p = 0.014), vosaroxin (p = 0.042), or radiation alone (p = 0.039) after 24 hr. In vivo tumor growth delay was 1.5 days for vosaroxin alone (IV 10 mg/kg), 1.0 days for radiation (3 Gy) alone, and 8.6 days for the group treated with vosaroxin 4 hours prior to radiation.

Conclusions

Vosaroxin enhanced tumor cell radiosensitivity in vitro and in vivo. The mechanism appears to be related to inhibition of DNA repair and increased mitotic catastrophe.

【 授权许可】

   
2012 Gordon et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Pommier Y, Leo E, Zhang H, Marchand C: DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010, 17(5):421-433.
• [2]Beauchesne P, Soler C, Rusch P, Fotso MJ, Duthel R, Schmitt T, Brunon J: Phase II study of a radiotherapy/etoposide combination for patients with newly malignant gliomas. Cancer Chemother Pharmacol 1999, 44(3):210-216.
• [3]Hayashi S, Hatashita M, Matsumoto H, Shioura H, Kitai R, Kano E: Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction. Int J Mol Med 2006, 18(5):909-915.
• [4]Chen Y, Lin TY, Chen JC, Yang HZ, Tseng SH: GL331, a topoisomerase II inhibitor, induces radiosensitization of human glioma cells. Anticancer Res 2006, 26(3A):2149-2156.
• [5]Mills DA, Fekrazad HM, Verschraegen CF: SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers. Curr Opin Investig Drugs 2008, 9(6):647-657.
• [6]Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA: Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol 2009, 64(1):53-65.
• [7]Wright J, Hyde J, Silverman JA, Walker DH, Arkin MR: SNS-595 has synergistic activity in vitro with DNA damaging agents and antimetabolites. AACR Meeting Abstracts 2006, 2006(1):504.
• [8]Xu B, Kim ST, Lim DS, Kastan MB: Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 2002, 22(4):1049-1059.
• [9]Xu B, Kastan MB: Analyzing cell cycle checkpoints after ionizing radiation. Methods Mol Biol 2004, 281:283-292.
• [10]Avondoglio D, Scott T, Kil W, Sproull M, Tofilon P, Camphausen K: High throughput evaluation of gamma-H2AX. Radiat Oncol 2009, 4(1):31. BioMed Central Full Text
• [11]Wong O, A C, Nguyen T, Stockett D, Yang W, RS M, JA F, Hawtin R: Voreloxin (formerly SNS-595) is a potent DNA intercalator and topoisomerase II poison that induces cell cycle depndent DNA damage and rapid apoptosis in cancer cell lines. 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics 2008.
• [12]Giocanti N, Hennequin C, Balosso J, Mahler M, Favaudon V: DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 1993, 53(9):2105-2111.
• [13]Clifford B, Beljin M, Stark GR, Taylor WR: G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res 2003, 63(14):4074-4081.